Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CardiAMP by BioCardia for Myocardial Ischemia: Likelihood of Approval
CardiAMP is under clinical development by BioCardia and currently in Phase III for Myocardial Ischemia. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of BioCardia's CardiAMP?
CardiAMP is a cell therapy commercialized by BioCardia, with a leading Phase III program in Systolic Heart Failure. According to...
CardiAMP by BioCardia for Systolic Heart Failure: Likelihood of Approval
CardiAMP is under clinical development by BioCardia and currently in Phase III for Systolic Heart Failure. According to GlobalData, Phase...